Mepolizumab in patients ≥3 exacerbations and eosinophil count ≥300 cells/µL
Sign Up to like & getrecommendations! Published in 2017 at "European Respiratory Journal"
DOI: 10.1183/1393003.congress-2017.pa3958
Abstract: Rationale: The PH3 mepolizumab (mepo) MENSA (M) study included patients (pt) with a history of ≥2 exacerbations in the year (yr) preceding randomization, receiving high dose ICS + ≥1 additional asthma controller, and blood eosinophils… read more here.
Keywords: sub pop; pbo; rate; mepo ... See more keywords